Causes of death, 2001: 1. Infectious and parasitic diseases: 14.9 million 2. Heart diseases: 11.1 million 3. Cancers: 7.3 million 4. Stroke: 5.5 million.

Slides:



Advertisements
Similar presentations
Cholesterol Metabolism By Amr S. Moustafa, M.D.; Ph.D.
Advertisements

Figure, Head group attachment Membrane phospholipids:
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
Lipid Biosynthesis C483 Spring Which of these is NOT a difference between fatty acid synthesis and beta oxidation? A)Synthesis requires an enzyme.
Cholesterol Synthesis
Lipoprotein Structure, Function, and Metabolism
Cholesterol and Steroid Metabolism Dr. Nikhat Siddiqi1.
Statin Drugs Cholesterol lowering drugs. Individual level risk factors for cardiovascular disease High Blood Pressure High Blood Cholesterol Tobacco Use.
Cholesterol and Heart Disease. Plaques Buildup in arteries is composed of proteins, lipids, and cholesterol When blood vessels are plugged up, you get.
The HMG-Co-A reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Youssef, et. al.
Cholesterol and Bile Acid Metabolism
COMPOSITION OF LIPIDS Lipoproteins Apolipoproteins Lipoproteins Apolipoproteins Cholesterol Protein Triglyceride Phospholipid.
Lipid Metabolism 3: Cholesterol biosynthesis, lipoprotein metabolism, steroid and eicosanoid synthesis Bioc 460 Spring Lecture 37 (Miesfeld) Steroids.
Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) October 18, 2006 Frank F. Vincenzi.
Substrates for lipid synthesis Phosphatidate is a precursor of storage and membrane lipids Formed by the addition of two fatty acids to glycerol 3-phosphate.
Anti-Hypercholesterolemic Agents  Biosynthesis and Metabolism of Cholesterol  What is arteriosclerosis? - Link between arteriosclerosis and cholesterol.
Statins: Powerful Inhibitors of Cholesterol Biosynthesis.
Cholesterol Cholesterol Sources:
Cholesterol synthesis and breakdown Dr. Carolyn K. Suzuki 1.
The Antihyperlipidemic Medications l Classifications of Lipoproteins – Chylomicrons l Formed in the mucosal cells of the gut l Protein coated dietary lipids.
Plasma lipoproteins. Generalized structure of a plasma lipoprotein.
 The third major class of lipids  The three cyclohexane rings (A, B, C) are connected to a cyclopentane ring (D).  Significantly different structure.
Kirk Mykytyn, Ph.D. Department of Pharmacology
Energy economy of the cells
A New Statin Drug: A Brief History of My Career Bonny Ortolano, Ph.D. Genome Pharmaceuticals Cambridge, Massachusetts.
LECT 22: LIPIDS, MEMBRANES, AND CHOLESTEROL Lipids and cholesterol in the body derive from food intake and from de novo synthesis. Phospholipids are principle.
LIPID METABOLISM: CHOLESTEROL METABOLISM. Functions of Cholesterol a precursor of steroid hormones (progesterone, testosterone, estradiol, cortisol, etc.)
Inhibition of Cholesterol Biosynthesis By Peter Riedell Medicinal Chemistry Dr. Buynak April 6, 2006.
Cholesterol Metabolism Southwestern Medical School Dallas, Texas.
CHOLESTEROL 10/02-03/07 I.LEARNING OBJECTIVES 1) To identify the structure of cholesterol 2) To outline the synthesis of cholesterol 3) To describe the.
Cholesterol Metabolism Cardiovascular Block. Overview Introduction Cholesterol structure Cholesteryl esters Cholesterol synthesis Rate limiting step Regulation.
Cholesterol Metabolism
Cholesterol metabolism: INTRODUCTION  Cholesterol is a sterol, present in cell membrane, brain and lipoprotein  It is a precursor for all steroids 
Case 15 Andrea De Mesa. Patient history A 44 y/o male, single, undergoes cardiovascular screening on advice of his attending physician. He is a smoker.
Lipogenesis. Metabolism of cholesterol.
Lipid Homeostasis and Transport CH353 February 12, 2008.
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
Cholesterol metabolism Structure of cholesterol OH is polar part The ring is non polar part Cholesterol ester (CE) is completely non polar.
Figure, Head group attachment Membrane phospholipids:
Lipid Metabolism Chapter 29, Stryer Short Course.
Hyperlipidemia Hyperlipidemia and hyperlipoproteinemia are general terms for elevated concentrations of lipids and lipoproteins in the blood. hypercholesterolemia.
TM © 1999 Professional Postgraduate Services ® Perspectives on Lipid-Lowering Therapy With HMG-CoA Reductase Inhibitors.
Chapter 21 Agents Used in the Treatment of Hyperlipidemia.
Cholesterol Metabolism.  The chemical and biochemical aspects of cholesterol regarding structure, distribution and biological functions in human body.
Anti hyperlipidemic drugs (lipid lowering drugs) Department of Pharmacology Faculty of Medicine AIMST UNIVERSITY 5 September 2012.
HYPERLIPIDEMIA  Coronary heart disease (CHD) is the cause of about half of all deaths. The incidence of CHD is correlated with elevated levels of low-density.
Genetics of Familial Hypercholesterolemia
Atorvastatin Calcium Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of.
Cholesterol metabolism
Hyperlipidemias.
CHOLESTEROL BIOSYNTHESIS
Statins induced myopathy
Cholesterol and its transport
Cholesterol Metabolism
Anti-Hypercholesterolemic Agents
Formative Test.
Anti-Hypercholesterolemic Agents
Cholesterol Synthesis, Transport, & Excretion
Biosynthesis and Metabolism of Cholesterol
Antilipemic Agents Lilley Pharmacology Text: Chapter 27
Updates in Cardiovascular Medicine
Joseph L. Goldstein, Michael S. Brown  Cell 
Committed step in cholesterol biosynthesis
Protein Sensors for Membrane Sterols
Major classes of drugs to reduce lipids
Statins Molecular mechanisms of action SREBP feedback control
Cholesterol Metabolism
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Section 6: Update on lipid treatment guidelines
Presentation transcript:

Causes of death, 2001: 1. Infectious and parasitic diseases: 14.9 million 2. Heart diseases: 11.1 million 3. Cancers: 7.3 million 4. Stroke: 5.5 million 5. Respiratory diseases: 3.6 million 6. Accidents, fires, drowning, etc.: 3.5 million 7. Maternal and perinatal: 3.0 million 8. Violence (war, homicide, suicide): 1.6 million World Health Organization World Health Report 2002 Population: 6,122,210,000 Deaths: 56,554,000 USA

Atherosclerosis

Familial Hypercholesterolemia (FH) Xanthoma Heterozygotes (1:500) mg/dl plasma cholesterol Xanathomas in third decade Coronary heart disease in fourth decade Treat w/ statins and bile acid binding resins Homozygotes (1:10^6) mg/dl plasma cholesterol Xanthomas at birth Death by MI before age 30 Treat w/ plasma LDL apheresis

Cholesterol 1) Acetyl-CoA  HMG-CoA  Mevalonate 2) Mevalonate (C 6 ) + 3ATP  Isopentenyl-PP i (C 5 “isoprene”) + CO 2 + 3ADP + P i 3) 6 Isoprene units (C 5 )  Squalene (C 30 ) 4) Squalene (C 30 )  Cholesterol (C 27 )

Isopentylpyrophosphate (MEV Pathway)

Lipid Trafficking Enzymes Also CETP

Lipoprotein Transport

Sterol Regulation of Transcription by SREBP SREPB Transcription Factor Localization ER RetentionProteases E.R. Golgi. Nucleus SCAP/Insig proteins also (HMG CoA R) S1PS2P SSD

The Statins SHORT HISTORY 1976 Mevastatin from Penicillinum citrinum 1980 Mevinolin from Aspergillus terreus 1987 FDA approves Lovastatin 1988 Lovastatin not effective in FH homozygotes 1995 Pravastatin decreases heart transplant rejection and mortality independently of lowering cholesterol levels

Isoprenoids in Humans 1.Steroids Hormones 2.Metabolites (Q, Vit. E, K, Retinal, 25,000 terpenoids) 3.Isopentyl adenosine (tRNA) 4.Dolichol (N-linked glycosylation) 5.Protein Prenylation

Isoprenoids in G Protein Signaling Heterotrimeric (GPCR’s) “Small” (RTK’s)

Cell Mediated Adaptive Immune Response

MHC Antigen Presentation

The MHC Molecules Class IClass II

Tc/MHC1/CD8 versus Th/MHC2/CD4

Th1 Helper Cells (macrophage/inflammatory)

Th2 Helper Cells (B cell response) also mast cell degranulation and eosinophil activation high [antigen], nonprofessional

Th1 vs. Th2 Maturation extracellular pathogens e.g. helminths also oral antigens LFA-1 !

Th1 vs. Th2 Antagonism

MHC II Transcription by CIITA

Alberts, A.W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 77, (1980). Uauy, R., Vega, G.L., Grundy, S.M. & Bilheimer, D.M. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr 113, (1988). Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, (2002). How Do Statins Work? Reported to: Decrease occurrence of AD by 70% in retrospective study Suppress MS (clinical trials) Block SMC proliferation/migration in vitro Modulate NF-  B Function in vitro Block IFN-  induced MHCII expression in vitro Suppress expression/secretion of immunoinflammatory molecules in vitro Direct inhibition of LFA-1 Most in vitro effects reversed by mevalonate, transF, transGG, but not cisF, cisGG, squalene, isopentyl adenosine or ubiquinone